Gilead Sciences extends offer to acquire Arcellx until late April
Gilead Sciences extends offer to acquire Arcellx until late April
Gilead Sciences has officially extended its tender offer to acquire Arcellx, Inc. until April 24, 2026.
orgGilead Sciences
orgArcellx, Inc.
This significant $7.8 billion deal is centered on the acquisition of the investigational BCMA-directed CAR T-cell therapy known as anito-cel, which treats relapsed or refractory multiple myeloma.
techBCMA-directed CAR T-cell therapy
techanito-cel
conceptmultiple myeloma
Under the offer terms, Gilead will pay $115 per share in cash, with an additional $5 contingent value right (CVR) if specific sales milestones for anito-cel are met by 2029.
conceptcontingent value right
techanito-cel
This acquisition represents a major step for Gilead in the competitive field of multiple myeloma treatment as they look toward potential commercialization.
conceptmultiple myeloma
